Analyst Price Targets — CLGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 2, 2024 11:47 am | Swayampakula Ramakanth | H.C. Wainwright | $11.00 | $4.34 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Collplant Holdings Inc. (CLGN) |
| August 5, 2024 7:52 am | Jason Kolbert | EF Hutton | $14.00 | $4.65 | StreetInsider | EF Hutton Starts Collplant Holdings Inc. (CLGN) at Buy |
Latest News for CLGN
REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the Company's…
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire
REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics applications, today announced financial results for the first quarter of 2026 and provided a corporate update. "In the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLGN.
U.S. House Trading
No House trades found for CLGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.